Conventional allogeneic hematopoietic stem cell transplantation (HSCT) strategies rely both on the high-dose combination chemotherapy or chemotherapy with high-dose total body irradiation conditioning and the allogeneic graft-versustumor effect to eradicate residual leukemia. Conventional HSCT are associated with significant regimen-related toxicities, limiting the application of most of these approaches to patients under the age of 55 years. In an attempt to extend allogeneic HSCT to elderly individuals, novel nonmyeloablative conditioning regimens have been developed in which the burden of tumor eradication has been shifted almost entirely toward the allogeneic graft-versus-leukemia effect.
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The nonmyeloablative HSCT regimen developed in Seattle uses a limited course of novel postgrafting immunosuppression to both ensure allogeneic engraftment and prevent serious graft-versus-host disease (GVHD), while maintaining graftversus-tumor effects. In our canine model and in human transplantation using HLA-identical sibling (DLA-identical littermate) grafts, both host-versus-graft and graft-versus-host reactions are mediated by T cells, suggesting that T celldirected therapies might effectively modulate both effects. One T cell-specific agent used in this setting is mycophenolate mofetil (MMF), which blocks an important enzyme in the de novo purine salvage pathway. We found a synergistic immunosuppressive effect when we combined MMF with cyclosporin A (CsA), a T cell activation blocker. Using these two agents to induce postgrafting immunosuppression in a canine model, we demonstrated that in combination with a very low and sublethal dose of total body irradiation (2 Gy delivered at 0.07 Gy/min), consistent engraftment could be accomplished. 1 The immunosuppressive effect of MMF/CsA on engraftment was comparable to that of an added single dose of 7.2 Gy total body irradiation (total dose 9.2 Gy) otherwise needed before HSCT. Administration of MMF and CsA for no more than 5 weeks after HSCT allowed the allograft to be maintained in 11 of 12 dogs studied. The granulocyte nadir was just below 1000/l and the platelet nadir was 30 000/l, demonstrating that this conditioning regimen was not myeloablative. In fact, 28 of 29 dogs given 2 Gy total body irradiation and no subsequent marrow grafts survived with spontaneous return of marrow function. 2 Chimerism studies on peripheral blood, marrow and lymph node compartments demonstrated mixed donor/host hematopoietic chimerism for now more than 3 years after allogeneic HSCT. We also demonstrated that full donor chimerism in transplanted dogs could be induced by lymphocyte infusions from marrow donors sensitized to host minor histocompatibility antigens. 3 In late 1997, we translated the nonmyeloablative HSCT approach developed in the canine model to the treatment of patients with hematologic diseases. 4 In 1998, we formed a consortium with colleagues at Stanford University, City of Hope, the University of Leipzig in Germany and then seven other centers in three countries to ask whether the regimen of 2 Gy total body irradiation and MMF/CsA could be implemented broadly. Using this regimen with or without three doses of fludarabine, we have successfully transplanted over 350 paitents with hematologic malignancies, 250 of whom received grafts from HLA-identical siblings and 100 from unrelated volunteer donors. Given the relative success of conventional HSCT in younger patients, we chose to include only those patients who were not eligible for conventional HSCT, either because they were elderly or had medical contraindications to such a transplant. G-CSF mobilized donor peripheral blood mononuclear cells were used as the stem cell source. The regimen was very well tolerated. The median granulocyte count nadir among the first 87 patients was 750/l and the median platelet nadir was 100 000/l. As a result, the patients could be transplanted in an outpatient setting. Only 23% of patients required platelet transfusions. Chimerism studies showed that by day 28, most of the marrow was donor-derived. T cells tended to lag behind and were of mixed donor/host origin (mixed chimerism) to day 120 in most patients.
Thus far, long-term survival data are available on 17 acute myeloid leukemia (AML) patients treated with regimen (Refs 4, 5 and unpublished data). Of these, 59% are alive and 41% have died. Of those who died, two were in remission at 5 months and 6 months after HSCT. Both died from infections associated with complications of GVHD. Five patients relapsed and died at 3 to 6 months after HSCT. Of the 10 who are alive, all are in complete remission. The six first-remission patients were all older than 60 years and have been in remission for a median of 21 (range, 4-25) months. Two patients who were transplanted in second and third remissions are alive and in remission at 5 and 11 months, as are two patients with primary induction failure at 27 and 30 months. These results suggest graft-versus-leukemia effects in some patients, but not in others. Whether that is because of lack of expression of minor histocompatibility antigens on the cell surfaces from patients without such an effect or because of the leukemic cells outgrowing the immune effects of the donor Leukemia T cells remains to be determined. Clearly, there is still work to be done.
For HLA-matched unrelated donor transplants, the regimen was modified to include three doses of fludarabine and to extend MMF to day 40 with subsequent taper to day 96 and CsA to day 100 with taper to day 180. Of seven patients with AML transplanted with this regimen, four had either primary refractory disease or were in advanced relapse and were transplanted without any further chemotherapy. Three are in remission beyond 1 year and one relapsed and died at 7 months. While the marrows of these patients contained leukemic blasts at the time of HSCT, they were often clear by day 28.
We have recently investigated whether external beam total body irradiation in this regimen could be replaced by radiolabeled monoclonal antibodies. In canine studies, we have employed an antibody to CD45 that was labeled with bismuth-213, an alpha emitter with a half-life of 47 min that deposits its considerable energy within a 40-90 radius. We injected the antibody isotope conjugate on days −3 and −2, and injected bone marrow on day 0. 6 We then administered MMF and CsA for 28 and 35 days, respectively. Chimerism studies of peripheral blood mononuclear cells showed both donor and host markers coexisting. In subsequent experiments, we have looked at an antibody to the T cell receptor to which we coupled bismuth-213, and again have seen engraftment. In the future, it is entirely possible that we could replace the external beam total body irradiation with an antibody isotope conjugate, limiting the toxicity to other organs.
In summary, we have developed a novel immunosuppressive regimen that enables successful engraftment of allogeneic stem cells without full myeloablation or significant associated regimen-related morbidity. The kinetics of engraftment using our MMF/CsA regimen demonstrated mixed chimerism at day 28 with subsequent slow conversion to full donor chimerism in many patients up to day 180. The graft-versus-leukemia effect was achieved without significant graft-versus-host disease in some patients. Future directions include application of this regiment to lower risk patients and use of radiolabeled targeting antibodies to replace external beam irradiation.
